Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/94986
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Outcome of central nervous system relapses in childhood acute lymphoblastic leukaemia - prospective open cohort analyses of the ALLR3 trial
Author: Masurekar, A.
Parker, C.
Shanyinde, M.
Moorman, A.
Hancock, J.
Sutton, R.
Ancliff, P.
Morgan, M.
Goulden, N.
Fraser, C.
Hoogerbrugge, P.
Revesz, T.
Darbyshire, P.
Krishnan, S.
Love, S.
Saha, V.
Citation: PLoS One, 2014; 9(10):e108107-1-e108107-13
Publisher: Public Library of Science
Issue Date: 2014
ISSN: 1932-6203
1932-6203
Editor: Baer, M.
Statement of
Responsibility: 
Ashish Narayan Masurekar, Catriona A. Parker, ., Milensu Shanyinde, Anthony V. Moorman, Jeremy P. Hancock, Rosemary Sutton, Philip J. Ancliff, Mary Morgan, Nicholas J. Goulden, Chris Fraser, Peter M. Hoogerbrugge, Tamas Revesz, Philip J. Darbyshire, Shekhar Krishnan, Sharon B. Love, Vaskar Saha
Abstract: The outcomes of Central Nervous System (CNS) relapses in children with acute lymphoblastic leukaemia (ALL) treated in the ALL R3 trial, between January 2003 and March 2011 were analysed. Patients were risk stratified, to receive a matched donor allogeneic transplant or fractionated cranial irradiation with continued treatment for two years. A randomisation of Idarubicin with Mitoxantrone closed in December 2007 in favour of Mitoxantrone. The estimated 3-year progression free survival for combined and isolated CNS disease were 40.6% (25·1, 55·6) and 38.0% (26.2, 49.7) respectively. Univariate analysis showed a significantly better survival for age <10 years, progenitor-B cell disease, good-risk cytogenetics and those receiving Mitoxantrone. Adjusting for these variables (age, time to relapse, cytogenetics, treatment drug and gender) a multivariate analysis, showed a poorer outcome for those with combined CNS relapse (HR 2·64, 95% CI 1·32, 5·31, p = 0·006 for OS). ALL R3 showed an improvement in outcome for CNS relapses treated with Mitoxantrone compared to Idarubicin; a potential benefit for matched donor transplant for those with very early and early isolated-CNS relapses. TRIAL REGISTRATION: Controlled-Trials.com ISRCTN45724312.
Keywords: Bone Marrow
Humans
Central Nervous System Neoplasms
Neoplasm Recurrence, Local
Treatment Outcome
Hematopoietic Stem Cell Transplantation
Transplantation, Homologous
Odds Ratio
Risk Factors
Cohort Studies
Adolescent
Child
Child, Preschool
Female
Male
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Chemoradiotherapy
Rights: © 2014 Masurekar et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
DOI: 10.1371/journal.pone.0108107
Grant ID: http://purl.org/au-research/grants/nhmrc/1024232
Appears in Collections:Aurora harvest 7
Medicine publications

Files in This Item:
File Description SizeFormat 
hdl_94986.pdfPublished version997.04 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.